BLU-263

Phase 1Small molecule

BBlueprint Medicines

BLU-263 is one of 22 small molecule programs targeting Systemic Mastocytosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic MastocytosisActive, not recruiting

Systemic MastocytosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Systemic Mastocytosis

#DrugCompanyPhaseTrials

Afinitor

Leustatin

Prolia

1 4

Plaquenil

Alnylam Pharmaceuticals

Phase 3

1 5

Rydapt

Novartis

Phase 2

3 6

17-AAG

Bristol-Myers Squibb

Phase 2

1 7

Adcetris

Pfizer

Phase 2

1 8

Masitinib

AAB Science

Phase 3

2 9

Ayvakit

BBlueprint Medicines

Phase 2

4 10

Imbruvica

PPharmacyclics LLC.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Systemic Mastocytosis1 trial

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Terminated·BBlueprint Medicines·Phase 1·NCT05609942·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BLU-263. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BLU-263 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BLU-263. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Blueprint Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBlueprint Medicines

BLU-263

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Systemic Mastocytosis1 trial

References

Drug Info

Quick Facts

Related News